Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Published Date: 25 Dec 2025

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Vaccine shows promise for pancreatic cancer, study finds

2.

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

3.

FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

Tumor characteristics found to differ for melanomas in children, teens and young adults


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot